Printer Friendly

Moberg Pharma announces signing of exclusive license agreement with Bayer for commercialisation of MOB-015 in Europe.

M2 EQUITYBITES-February 12, 2019-Moberg Pharma announces signing of exclusive license agreement with Bayer for commercialisation of MOB-015 in Europe

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Swedish pharmaceutical company Moberg Pharma AB (STO:MOB) announced on Monday the signing of an exclusive license agreement with the Consumer Health division of Bayer AG (Xetra:BAYN) for commercialisation of MOB-015 in Europe.

MOB-015 is a new topical treatment of onychomycosis based on Moberg Pharma's patented proprietary formulation of terbinafine.

Under the terms of the license agreement, Moberg Pharma will finalise the ongoing phase III programme, complete registration in Europe and provide supply for the product. Bayer will be marketing, distributing and selling MOB-015 in Europe upon completion of phase III clinical development and registration.

Also, Moberg Pharma is eligible to receive up to EUR50m in milestone payments, including EUR1.5m paid at signing. The majority of the milestone payments are contingent on sales targets, with the balance contingent on development and regulatory milestones. Moberg Pharma will also receive supply fees including royalties.

Reportedly, this is the second major agreement for MOB-015.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 12, 2019
Words:191
Previous Article:Omnicom announces 8.3% higher stock dividend of USD0.65 per share.
Next Article:Pandora reports on share buyback programme.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters